This is a Senate resolution expressing support for keeping mifepristone—a medication used to end early pregnancies and manage miscarriages—accessible to patients. The resolution emphasizes that over 25 years of scientific research and hundreds of peer-reviewed studies have proven mifepristone is safe and effective. It argues that the FDA's regulations governing this medication should be based on scientific evidence rather than politics, and that current policies should allow the medication to be prescribed through telemedicine and dispensed by mail or at pharmacies, as the FDA determined in 2023. The resolution highlights that medication abortion now accounts for 63% of all abortions in the United States and notes that access restrictions disproportionately harm Black people, Indigenous people, people of color, immigrants, people with lower incomes, rural communities, LGBTQ+ people, people with disabilities, and those experiencing domestic violence. The resolution calls on the FDA to maintain transparent, science-based policies and to preserve and expand access to medication abortion care to ensure equitable treatment across all communities.

Warren, Elizabeth

A resolution expressing the sense of the Senate that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.